Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter, phase III study comparing anthracyclines
followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant
therapy in patients with triple-negative breast cancer.
Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who
need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant
chemotherapy for TNBC are eligible.